All News
Filter News
Found 22,054 articles
-
Genmab Publishes 2023 Annual Report
2/14/2024
Genmab A/S announced the publication of its Annual Report for 2023.
-
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
2/14/2024
Gain Therapeutics, Inc., a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announced it is holding a 2024 Research & Development update on recent in vivo data for GT-02287 along with valuable insights from Key Opinion Leaders.
-
Hemogenyx Pharmaceuticals PLC Announces CBR Intranasal Delivery
2/14/2024
Hemogenyx Pharmaceuticals plc announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor can be delivered intranasally in the form of messenger RNA for the potential treatment of airborne viral infections.
-
Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference
2/14/2024
Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, Miami Beach, FL.
-
Cingulate Appoints Jay Roberts, Bryan Lawrence, and Jeff Ervin to its Board of Directors
2/13/2024
Cingulate Inc. announced that it has appointed three new directors to its board: Jay Roberts, Bryan Lawrence, and Jeff Ervin.
-
Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer
2/13/2024
Enigma Biomedical USA announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer. Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
-
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
2/13/2024
Onconetix, Inc. announced the appointment of Ajit Singh, Ph.D. and Thomas Meier, Ph.D. to its Board of Directors.
-
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
2/13/2024
Phathom Pharmaceuticals, Inc. today announced the placement of VOQUEZNA® (vonoprazan) tablets for the treatment of adults with Erosive Esophagitis, commonly referred to as Erosive GERD (gastroesophageal reflux disease), and relief of heartburn associated with Erosive Esophagitis on the Express Scripts national formularies, effective immediately.
-
Molecular Assemblies Announces the Appointment of Two Industry Leaders to Its Commercial-Technology Advisory Board
2/13/2024
Molecular Assemblies, Inc. today announced the addition of two industry leaders to its Commercial-Technology Advisory Board (CTAB), which includes experts in the commercialization of nucleic acid technologies and innovative life science product solutions.
-
Krystal Biotech Receives FDA Fast Track Designation for Inhaled Oncology Candidate KB707 to Treat Solid Tumors of the Lung
2/13/2024
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for inhaled KB707 for the treatment of patients with solid tumors with pulmonary metastases that are relapsed or refractory to standard of care therapy.
-
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases
2/13/2024
FibroBiologics Presents Preclinical Data at the 2024 Keystone Symposia for Systemic Autoimmune and Autoinflammatory Diseases.
-
Lineage Announces FDA Clearance of IND Amendment for OPC1 Cell Transplant for the Treatment of Spinal Cord Injury
2/13/2024
Lineage Cell Therapeutics, Inc. announced today the clearance, by the U.S. Food and Drug Administration (FDA), of its Investigational New Drug amendment (INDa) for OPC1.
-
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
2/13/2024
Sudo Biosciences today announced that during January 2024, it completed a second close of its Series B financing, raising an additional $30 million from new investors Dementia Discovery Fund.
-
Dave Amerson and Tyler Binney Add Their Experience Commercializing Disruptive Technologies to Intrinsic Therapeutics' Board of Directors
2/13/2024
Intrinsic Therapeutics, Inc. announced the appointment of Dave Amerson and Tyler Binney to its Board of Directors.
-
Kenvue to Present at the Consumer Analyst Group of New York Conference on February 23, 2024
2/13/2024
Kenvue Inc. today announced Thibaut Mongon, Chief Executive Officer, and Paul Ruh, Chief Financial Officer, will present at the Consumer Analyst Group of New York (CAGNY) Conference in Boca Raton, Florida, on Friday, February 23, 2024, at 10:00 a.m. Eastern Time.
-
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
2/12/2024
Connect Biopharma Holdings Limited announced the appointment of James Zuie-chin Huang, M.B.A., to its Board of Directors effective immediately.
-
HTuO Biosciences Joins Johnson & Johnson Innovation - JLABS
2/12/2024
HTuO Biosciences announces it has joined Johnson & Johnson Innovation - JLABS as a resident virtual company.
-
GID BIO completes enrollment for randomized double-blinded pivotal Phase III cell therapy study for treatment of knee osteoarthritis
2/12/2024
GID BIO, Inc. completed enrollment for the first of two pivotal Phase III studies to investigate the use of your own stromal vascular fraction (SVF) cells to treat osteoarthritis of the knee.
-
Johnson & Johnson to Participate in the Leerink Global Biopharma Conference
2/12/2024
Johnson & Johnson (NYSE: JNJ) will participate in the Leerink Global Biopharma Conference on Tuesday, March 12th, at the Fontainebleau Miami Beach, FL.
-
The CEOs of BMS, J&J and Merck testified Thursday before the Senate health committee that pharmacy benefit managers bear much of the blame for high pricing, while declining to commit to price cuts.